Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Interim Management Statement

6 Nov 2009 07:00

RNS Number : 0801C
Stanelco PLC
06 November 2009
 



6 November 2009

Stanelco plc ("the Company" or "the Group")

Interim Management Statement

Stanelco plc issues its interim management statement for the period from 1 January 2009 to 5 November 2009, as required by the UK Listing Authority's Disclosure and Transparency Rules.

Highlights

Sales to 30 September up 12% to £13.4m

Trading performance in line with Board's expectations:

Continued growth in bioplastics division driven by interest in adopting sustainable products; increasing applications in new sectors

Radio frequency applications division sales order pipeline continued to strengthen; growing overseas sales in China and India

Closing cash position at 30 September £3.7m, increased by working capital improvements

Board confident in full year outlook

Trading Update

Group revenues grew strongly during the nine months to 30 September 2009 and the Group's overall trading performance was in line with the Board's expectations.

Group revenues increased from £12.0m to £13.4m in the nine months to 30 September 2009, an increase of 12% compared with the same period last year. This reflected a 29% increase in bioplastic sales made directly by the Company, a 30% increase in sales in RF Applications division and an 8% increase in third party sales from our joint venture, Biotec.

Our cash position at 30 September 2009 was £3.7m, strengthened since the half year by working capital improvements, including a reduction in stock levels following the summer production holiday.

Bioplastics division

In the Bioplastics division, the sales team that was established last year has had a number of successes in growing sales of the Group's existing biodegradable products into the market, delivering a 29% increase in the Company's bioplastic sales in the nine months to 30 September 2009. The division has broadened its customer base with over 40 new customers in 2009 and widened the set of end-use applications by a further 17 in the same period. The management remain encouraged by the division's opportunities for growth.

The product development team continues to work closely with a number of blue chip customers and mainstream plastics convertors to develop a widening range of biodegradable products that can substitute oil-based plastics. Whilst some of these development paths are still at an early stage, others are poised to deliver further growth in the coming months. The development team continues to focus on those accounts which we consider could have the maximum growth potential.

We continue to see strong demand for bioplastic products in the market, driven not only by concerns about waste disposal but also by the desire of many large corporations to switch to using sustainable resources in key brandsThis switch to the use of "renewable" materials in advance of legislation is seen as both a branding enhancement and a hedge against further oil based price rises.   Sectors in which we are gaining traction include packaging, waste disposal, paper products, personal care, horticulture and electronics. The sales development work undertaken in the USA over the past year is now also gaining momentum. 

Our joint venture, Biotec, delivered 8% growth in its third party sales for the 9 months to 30 September 2009  compared with the same period last year.

Radio Frequency (RF) applications division 

In the RF Applications division, the team has been fulfilling a number of significant orders that have been won in the nine months to 30 September 2009, including the £0.3m order for RF furnaces disclosed in our interim results. Sales in the period increased by 30% compared with the same period last year including growth in both optical fibre furnaces and more general industrial equipment in which we are building a portfolio of customers making repeat orders.  The sales order pipeline continues to strengthen with a particular emphasis on sales in India and China. As a result, a new sales consultant has now been appointed for Stanelco dedicated to the Indian market, as this territory shows signs of increasing growth in the next few years.

Outlook

The Board continues to be confident in the outlook for the full year. Our focus continues to be on working closely with customers with the potential to deliver increases in revenue, whilst considering acquisition opportunities and other paths that could significantly increase the scale of the business and deliver shareholder value. 

- Ends -

For further information please contact:

Paul Mines, Chief Executive, Stanelco plc

Sue Bygrave, Group Finance Director, Stanelco plc

Tel: +44 (0) 2380 867100

Jonathon Brill/Caroline Stewart

Financial Dynamics

Tel: +44 (0) 20 7831 3113

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBABRTMMJMBFL
Date   Source Headline
27th Apr 20071:34 pmRNSResult of AGM
27th Apr 20071:32 pmRNSDirectorate Change
26th Apr 20071:42 pmRNSAnnual Information Update
13th Apr 200712:29 pmRNSDirector's Dealing
30th Mar 20071:32 pmRNSAnnual Report and Accounts
23rd Mar 20075:09 pmRNSNotifiable Interest
21st Mar 20077:03 amRNSPreliminary Results
14th Mar 20075:59 pmRNSHolding(s) in Company
26th Feb 20077:01 amRNSBoard Appointment
23rd Feb 20073:18 pmRNSHolding(s) in Company
30th Jan 20079:00 amRNSNotice of Results
18th Dec 20064:58 pmRNSTotal Voting Rights
8th Dec 200612:31 pmRNSNotifiable Interest
28th Nov 20063:32 pmRNSNotifiable Interest
17th Nov 20063:33 pmRNSNotifiable Interest
16th Nov 20069:02 amRNSNotifiable Interest
14th Nov 20064:37 pmRNSDirectorate Change
14th Nov 20064:09 pmRNSDirector/PDMR Shareholding
14th Nov 20064:03 pmRNSNotifiable Interest
14th Nov 20069:55 amRNSNotifiable Interest
10th Nov 200610:29 amRNSHolding(s) in Company
9th Nov 200611:45 amRNSNotifiable Interest
8th Nov 20063:08 pmRNSNotifiable Interest
7th Nov 20068:01 amRNSIssue of Equity
6th Nov 200612:12 pmRNSResult of EGM
3rd Nov 20064:41 pmRNSNotifiable Interest
3rd Nov 20061:17 pmRNSOpen Offer Result - Amendment
2nd Nov 20066:03 pmRNSOpen Offer Result
31st Oct 200611:54 amRNSNotifiable Interest
17th Oct 20065:54 pmRNSNotifiable Interest
17th Oct 200610:44 amRNSNotifiable Interest
16th Oct 20063:17 pmRNSNotifiable Interest
12th Oct 200612:35 pmRNSDoc re. Posting of Prospectus
11th Oct 20061:09 pmRNSNotifiable Interest
9th Oct 200611:13 amRNSProposed Placing & Open Offer
5th Oct 200610:25 amRNSFinancing Update
3rd Oct 200612:56 pmRNSStatement re. Press Comment
2nd Oct 20064:41 pmRNSSecond Price Monitoring Extn
2nd Oct 20064:35 pmRNSPrice Monitoring Extension
8th Sep 20067:01 amRNSTrading Statement
17th Aug 20067:44 amRNSTrading Statement
16th Aug 20065:52 pmRNSAdditional Listing - AMEND
14th Aug 200611:55 amRNSAdditional Listing
10th Aug 200612:25 pmRNSRe Contract
14th Jul 20067:56 amRNSInterim Results - Replacement
14th Jul 20067:00 amRNSInterim Results
2nd Jun 200611:26 amRNSNew Ord Share Placing-Amendmt
2nd Jun 20068:45 amRNSNew Ordinary Share Placing
25th May 20067:02 amRNSWrap 100 FDA approval
16th May 200610:43 amRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.